GeminiBio Expands Board with Addition of Industry Veteran

Mr. Jeffrey Gatz Brings Track Record of Growing companies and expertise in the Life Science Tools space

WEST SACRAMENTO, Calif., April 1, 2025 /PRNewswire/ -- Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Jeffrey Gatz to its Board of Directors.  

GeminiBio provides serum, customized media, buffers, and process liquids to biopharma and advanced therapy companies focused on the research and production of mRNA, AAV, monoclonal antibody, and cell therapy technologies. The appointment of Jeffrey to the GeminiBio Board will provide the company with critical customer-oriented insights in the Pharma and Biotech industry.

Jeffrey Gatz is a seasoned executive with extensive experience in the biotechnology and life science sectors. He spent 26 years as CEO of BioIVT, a leading global provider of biological products for life sciences and pharmaceutical companies. Under his leadership, BioIVT expanded its portfolio of high-quality human and animal-derived products and services, strengthened its global presence, and built strategic partnerships across the life science industry. Mr. Gatz worked with four different private equity firms during his tenure at BioIVT, including Linden Capital Partners, BioIVT's current financial sponsor.  Known for his strategic vision as well as commercial and operational expertise, Mr. Gatz has helped lead more than 20 acquisitions and integrations. 

"Jeffrey's proven success expanding product and service offerings, both organically and inorganically, to address critical needs of life science researchers and developers has direct relevance to GeminiBio," said Brian Parker, Chief Executive Officer of GeminiBio, "we are eager to leverage Jeffrey's insight and guidance as we continue to develop and commercialize products and capabilities aimed at adding value to cell and advanced therapy developers and manufacturers."

Cory Stevenson, Executive Chairman of the GeminiBio board added, "I am excited to have Jeffrey join the GeminiBio board, as he adds the fantastic perspective of a dynamic life science tools manufacturer that has helped end customers advance their research, development, and manufacturing.  Jeffrey's experience and perspective will combine synergistically with the extensive cell therapy and biologic manufacturing expertise of the other GeminiBio board members."

"I am honored to join the GeminiBio board and am excited to work with the board of directors to support the company's strategic growth. Joining the GeminiBio board is sort of a homecoming for me, as I have had interactions with the company over many decades – I am anxious to dig in with Brian and his team to accelerate product development and bring differentiated value for both customers and the company." said Jeffrey Gatz.

Jeffrey also serves on the boards of life science companies Vector Laboratories and TransnetYX.

About GeminiBio

GeminiBio is a portfolio company of BelHealth Investment Partners.  GeminiBio was founded in 1985 and serves the global biopharma, and cell and gene therapy industries.  Its focus is on helping customers (from basic research to commercial production) accelerate the development of life-enhancing biotherapeutics by streamlining and improving their cell culture and process liquid manufacturing workflows.

The company provides critical raw materials used in cell therapy, gene therapy and biotherapeutics manufacturing – including serum, customized media and buffers solutions, and process liquids.  Located in West Sacramento, California, GeminiBio has 57,000 square feet of cGMP manufacturing space, segregated between animal origin-free and animal component manufacturing. GeminiBio is an ISO 13485:2016 certified, FDA-registered Class 1 Medical Device Manufacturer, aligned with 21 CFR Part 820.

For more information, visit www.geminibio.com.

Contact:
GeminiBio: Brian Parker
[email protected]
832.541.9668

About BelHealth Investment Partners
BelHealth Investment Partners, based in Fort Lauderdale, Florida, is a healthcare private equity firm focused on lower middle market companies. BelHealth acquires majority positions in entrepreneur-owned companies that it believes will benefit from its extensive investing, executive management and entrepreneurial experience.

For more information, visit www.belhealth.com

Contact:
BelHealth: Inder Tallur
[email protected]
917.975.6604

View original content to download multimedia:https://www.prnewswire.com/news-releases/geminibio-expands-board-with-addition-of-industry-veteran-302416714.html

SOURCE Gemini Bioproducts, LLC